Pleasing Signs As A Number Of Insiders Buy Altimmune Stock

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of Altimmune, Inc. (NASDAQ:ALT), it sends a favourable message

Simply Wall StOct 3 02:34

Altimmune's Phase 3 MASH Trial Puts Pemvidutide in the Spotlight for Investors

TipRanksSep 24 00:30

Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17

Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $18 to $17.

BenzingaSep 23 21:11

Evercore Maintains Altimmune(ALT.US) With Buy Rating, Cuts Target Price to $17

Evercore analyst Michael DiFiore maintains $Altimmune(ALT.US)$ with a buy rating, and adjusts the target price from $25 to $17.According to TipRanks data, the analyst has a success rate of 44.4% and

Futu NewsSep 23 20:31

Good news from Viking Therapeutics' weight-loss drug: even with the dosing frequency halved, it still maintains a 97% weight-loss rate.

Viking Therapeutics surged nearly 50% in pre-market trading on Tuesday after the biotech company announced that its experimental obesity drug, VK2735, helped patients maintain most of their weight loss even when the dosing frequency was reduced from weekly to every two weeks.

Zhitong FinanceSep 22 21:43

Novo-Nordisk A/S unveiled a $23 billion pipeline blueprint, but the market remained unimpressed! Investors are pressing for answers on "how to turn the tide against headwinds."

Novo-Nordisk A/S disappointed investors after failing to present a concrete turnaround plan to CEO Mike DuStall, following its loss of market leadership in the obesity segment to Eli Lilly and Co. The company pledged to launch more than five blockbuster drugs over the next few years and generate over $23 billion in new sales, but the presentation lacked specifics on how it intends to drive growth.

Zhitong FinanceSep 21 17:24